antibody

RAF1 Polyclonal Antibody

MBS125587

0.05 mg

230 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

western blot, immunocytochemistry

Antibody

RAF1 Polyclonal Antibody

RAF1

RAF1; CRAF; NS5; Raf-1; c-Raf

RAF proto-oncogene serine/threonine-protein kinase; RAF proto-oncogene serine/threonine-protein kinase; RAF proto-oncogene serine/threonine-protein kinase; Oncogene RAF1; proto-oncogene c-RAF; C-Raf proto-oncogene, serine/threonine kinase; v-raf-1 murine leukemia viral oncogene homolog 1; raf proto-oncogene serine/threonine protein kinase; Raf-1 proto-oncogene, serine/threonine kinase; Proto-oncogene c-RAF; cRaf; Raf-1

RAF1

RAF1; RAF1; NS5; CRAF; Raf-1; c-Raf; CMD1NN; RAF; cRaf

RAF1_HUMAN

Polyclonal

IgG

Rabbit

Human, Mouse, Rat

648

Affinity Purification

1mg/ml

Store at -20 degree C (regular) or -80 degree C (long term). Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Western Blot (WB), Immunofluorescence (IF)

WB: 1:500 - 1:2000. IF: 1:50 - 1:200

Species: Human. Route: Recombinant Protein

Immunogen: C term -peptide of human RAF1. Calculated Molecular Weight: 73kDa

Polyclonal

A-Raf, B-Raf and RAF1 (Raf-1) are the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway (1). Activation of RAF1 is the best understood and involves phosphorylation at multiple activating sites including Ser338, Tyr341, Thr491, Ser494, Ser497 and Ser499 (2). p21-activated protein kinase (PAK) has been shown to phosphorylate RAF1 at Ser338 and the Src family phosphorylates Tyr341 to induce RAF1 activity (3,4). Ser338 of RAF1 corresponds to similar sites in A-Raf (Ser299) and B-Raf (Ser445), although this site is constitutively phosphorylated in B-Raf (5). Inhibitory 14-3-3 binding sites on RAF1 (Ser259 and Ser621) can be phosphorylated by Akt and AMPK, respectively (6,7). While A-Raf, B-Raf and RAF1 are similar in sequence and function, differential regulation has been observed (8). Of particular interest, B-Raf contains three consensus Akt phosphorylation sites (Ser364, Ser428 and Thr439) and lacks a site equivalent to Tyr341 of RAF1 (8,9). The B-Raf mutation V600E results in elevated kinase activity and is commonly found in malignant melanoma (10). Six residues of RAF1 (Ser29, Ser43, Ser289, Ser296, Ser301 and Ser642) become hyperphosphorylated in a manner consistent with RAF1 inactivation. The hyperphosphorylation of these six sites is dependent on downstream MEK signaling and renders RAF1 unresponsive to subsequent activation events (11).

125651

P04049.1

P04049

648

AGE/RAGE Pathway 698754!!ARMS-mediated Activation Pathway 106466!!Activation Of NMDA Receptor Upon Glutamate Binding And Postsynaptic Events Pathway 161033!!Acute Myeloid Leukemia Pathway 83117!!Acute Myeloid Leukemia Pathway 529!!Adaptive Immune System Pathway 366160!!Alcoholism Pathway 585563!!Alcoholism Pathway 587116!!Axon Guidance Pathway 105688!!B Cell Receptor Signaling Pathway 198909

This gene is the cellular homolog of viral raf gene (v-raf). The encoded protein is a MAP kinase kinase kinase (MAP3K), which functions downstream of the Ras family of membrane associated GTPases to which it binds directly. Once activated, the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2, which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. Activated ERKs are pleiotropic effectors of cell physiology and play an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration. Mutations in this gene are associated with Noonan syndrome 5 and LEOPARD syndrome 2. [provided by RefSeq, Jul 2008]

0.05 mg

230 USD